| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-336
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-336 |
| filingDate |
2002-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2004-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2004517882-A |
| titleOfInvention |
Anticancer treatment using triptolide prodrug |
| abstract |
Water-soluble triptolide prodrugs are more effective in vivo in reducing tumor size at lower doses than the widely used chemotherapeutic agents 5-fluorouracil and irinotecan as anticancer agents Was found. In one aspect, the invention provides a method for anti-cancer treatment. The method comprises administering to a subject in need of such treatment an effective amount of a triptolide prodrug, represented by any of structures I-IV, or a pharmaceutically acceptable salt thereof, as shown and described below. Administering the acceptable salt in a pharmaceutically acceptable vehicle. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006503831-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012526148-A |
| priorityDate |
2001-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |